skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

Review

(2783) Views  (1268) Full article downloads

Authors: Katrine B Hansen, Tina Vilsbøll, Filip K Knop

Published Date May 2010 Volume 2010:3 Pages 155 - 163
DOI: http://dx.doi.org/10.2147/DMSO.S7004

Katrine B Hansen1, Tina Vilsbøll2, Filip K Knop2

1Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark

Abstract: Type 2 diabetes mellitus is a metabolic disease associated with low quality of life and early death. The goal in diabetes treatment is to prevent these outcomes by tight glycemic control and minimizing vascular risk factors. So far, even intensified combination regimen with the traditional antidiabetes agents have failed to obtain these goals. Incretin mimetics are a new class of antidiabetes drugs which involve modulation of the incretin system. They bind to and activate glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta-cells following which insulin secretion and synthesis are initiated. Since the compounds have no insulinotropic activity at lower glucose concentrations the risk of hypoglycemia – a well-known shortcoming of existing antidiabetes treatments – is low. Additionally, incretin mimetics have been shown to be associated with beneficial effects on cardiovascular risk factors such as weight loss, decrease in blood pressure and changes in lipid profile. Current clinical data on the two available incretin mimetics, exenatide and liraglutide, are evaluated in this review, focusing on pharmacology, efficacy, safety and tolerability. The review is built on a systematic PubMed and Medline search for publications with the key words GLP-1 receptor agonist, exenatide, liraglutide and type 2 diabetes mellitus up to January 2009.

Keywords: glucagon-like peptide-1 (GLP-1), exenatide, liraglutide, type 2 diabetes








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Risk management in the treatment of type 2 diabetes with pioglitazone
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Can a gentamicin-specific chart reduce neonatal medication errors?
Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Everolimus-eluting stents: update on current clinical studies
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio